Related Experiment Video
Updated: Jul 25, 2026
18:01
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
Published on: August 18, 2008
Interactions between loreclezole, chlormethiazole and pentobarbitone at GABA(A) receptors: functional and binding
1Department of Pharmacology, School of Pharmacy, University of London.
British Journal of Pharmacology
|August 1, 1997
Summary
Loreclezole, chlormethiazole, and pentobarbitone exhibit distinct actions on gamma-aminobutyric acid type A (GABA(A)) receptors. Chlormethiazole potentiates GABA(A) receptor responses, while loreclezole shows weaker potentiation and affects [3H]-flunitrazepam binding differently.
Area of Science:
- Neuropharmacology
- Molecular Neuroscience
- Receptor Pharmacology
Background:
- Gamma-aminobutyric acid type A (GABA(A)) receptors are crucial inhibitory neurotransmitter receptors in the central nervous system.
- Loreclezole, chlormethiazole, and pentobarbitone are known modulators of GABA(A) receptor function.
- Understanding their distinct interaction profiles is essential for developing targeted therapeutics.
Purpose of the Study:
- To investigate the interactions of loreclezole, chlormethiazole, and pentobarbitone on GABA(A) receptor-mediated responses in rat cuneate nucleus.
- To compare their modulatory effects on [3H]-flunitrazepam binding to synaptic membranes.
- To elucidate the distinct pharmacological profiles of these GABA(A) receptor ligands.
Main Methods:
- Electrophysiological recordings in rat cuneate nucleus slices to assess potentiation of muscimol-induced responses.
- In vitro binding assays using [3H]-flunitrazepam ([3H]-FNZ) on rat whole brain synaptic membranes.
- Scatchard analysis to determine binding kinetics (Bmax and K(D)) in the presence of drugs.
Main Results:
- Chlormethiazole significantly potentiated muscimol responses, while loreclezole exhibited weaker potentiation.
- Loreclezole enhanced [3H]-FNZ binding, indicating altered receptor conformation, with a decrease in dissociation constant (K(D)) but no change in maximum binding (Bmax).
- Loreclezole's potentiation effects were attenuated when combined with chlormethiazole or pentobarbitone, suggesting receptor desensitization.
Conclusions:
- Loreclezole, chlormethiazole, and pentobarbitone display significantly different mechanisms of action at GABA(A) receptors.
- Loreclezole's effects on [3H]-FNZ binding appear distinct from its GABA-potentiating actions and may involve direct receptor interactions.
- These findings highlight the complex pharmacology of GABA(A) receptor modulation by different drug classes.
More Related Videos
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Related Concept Videos
01:19Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...